Search alternatives:
increase decrease » increased release (Expand Search), increased crash (Expand Search)
i decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
i decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
241
-
242
-
243
-
244
-
245
-
246
-
247
-
248
-
249
-
250
Temperature effects on populations of <i>S. haematobium</i> and <i>S. mansoni</i> infections.
Published 2025Subjects: -
251
-
252
-
253
The relationship between residual shear strength and <i>JRC</i>, normal stress.
Published 2024Subjects: -
254
-
255
-
256
HFD decreases intermediate-term memory.
Published 2025“…Error bars indicate SD (n = 3. Student’s <i>t</i>-test, * p < 0.05). (C) Food intake was not significantly different between ND- and HFD-fed flies during the 1 hour. …”
-
257
-
258
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
259
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
260